Evidence map›Paper›PMID 27094150›Full record

ArticleBioorganic & medicinal chemistry2016

Engineered production of cancer targeting peptide (CTP)-containing C-1027 in Streptomyces globisporus and biological evaluation.

Wenli Li, Xiuling Li, Tingting Huang, Qihui Teng, Ivana Crnovcic, Christoph Rader, Ben Shen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wenli LiDivision of Pharmaceutical Sciences, University of Wisconsin, Madison, WI 53705, USA.
Xiuling LiDepartment of Cancer Biology, The Scripps Research Institute, Jupiter, FL 33458, USA.
Tingting HuangDepartment of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA.
Qihui TengDepartment of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA.
Ivana CrnovcicDepartment of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA.
Christoph RaderDepartment of Cancer Biology, The Scripps Research Institute, Jupiter, FL 33458, USA; Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL 33458, USA.
Ben ShenDivision of Pharmaceutical Sciences, University of Wisconsin, Madison, WI 53705, USA; Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA; Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL 33458, USA; Natural Products Library Initiative at The Scripps Research Institute, The Scripps Research Institute, Jupiter, FL 33458, USA. Electronic address: shenb@scripps.edu.
Scripps Research Institute · USUniversity of Wisconsin–Madison · US

Funding

Enediyne Biosynthesis and EngineeringR01CA078747 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SHEN, BEN · 1999 to 2015
$3.4M
NCI NIH HHS R01 CA078747
6 · The paper itself

Abstract

Conjugation of cancer targeting peptides (CTPs) with small molecular therapeutics has emerged as a promising strategy to deliver potent (but typically nonspecific) cytotoxic agents selectively to cancer cells. Here we report the engineered production of a CTP (NGR)-containing C-1027 and evaluation of its activity against selected cancer cell lines. C-1027 is an enediyne chromoprotein produced by Streptomyces globisporus, consisting of an apo-protein (CagA) and an enediyne chromophore (C-1027). NGR is a CTP that targets CD13 in tumor vasculature. S. globisporus SB1026, a recombinant strain engineered to encode CagA with the NGR sequence fused at its C-terminus, directly produces the NGR-containing C-1027 that is equally active as the native C-1027. Our results demonstrate the feasibility to produce CTP-containing enediyne chromoproteins by metabolic pathway engineering and microbial fermentation and will inspire efforts to engineer other CTP-containing drug binding proteins for targeted delivery.

Indexed as

AminoglycosidesAntineoplastic AgentsBacterial ProteinsCell Line, TumorEnediynesFeasibility StudiesFermentationHumansProtein EngineeringStreptomycesAminoglycosidesAntineoplastic AgentsBacterial ProteinsC 1027EnediynesC-1027CancerCancer targeting peptide (CTP)EnediyneStreptomyces globisporus

Identifiers

PMID27094150
PMCPMC4972678
OpenAlexW2320823775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.